カテゴリー： Market Monitor Global, 世界, 医療/バイオ

生物学的同等ペプチド医薬品のグローバル市場展望 2023年-2029年：テリパラチド（フォルテオ）、テドゥグルチド（ガテックス）、リラグルチド（ビクトーザ）

◆英語タイトル：Bioequivalent Peptide Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23DC14244）

◆商品コード：MMG23DC14244
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年12月
◆ページ数：72
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の生物学的同等ペプチド医薬品市場規模と予測を収録しています。・世界の生物学的同等ペプチド医薬品市場：売上、2018年-2023年、2024年-2029年
・世界の生物学的同等ペプチド医薬品市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の生物学的同等ペプチド医薬品市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「テリパラチド（フォルテオ）」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

生物学的同等ペプチド医薬品のグローバル主要企業は、Eli Lilly and Company、 Alvogen、 Pfenex、 HEC Pharm、 Bachem、 Bharat Pharmaceuticals、 Kingpep Biotechnology、 Ambio Pharmaceuticals、 Jiangsu Sinopep Allsino Biopharmaceutical、 Shanghai Shyndec Pharmaceutical、 Shenzhen Salubris Pharmaceuticals、 Shanghai United Cell Biotechnology、 Shenzhen JYMed Technology、 Wuxi Asiapeptide Biotechnologyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、生物学的同等ペプチド医薬品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の生物学的同等ペプチド医薬品市場：タイプ別、2018年-2023年、2024年-2029年
世界の生物学的同等ペプチド医薬品市場：タイプ別市場シェア、2022年
・テリパラチド（フォルテオ）、テドゥグルチド（ガテックス）、リラグルチド（ビクトーザ）

世界の生物学的同等ペプチド医薬品市場：用途別、2018年-2023年、2024年-2029年
世界の生物学的同等ペプチド医薬品市場：用途別市場シェア、2022年
・短腸症候群、骨粗鬆症、2型糖尿病、その他

世界の生物学的同等ペプチド医薬品市場：地域・国別、2018年-2023年、2024年-2029年
世界の生物学的同等ペプチド医薬品市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における生物学的同等ペプチド医薬品のグローバル売上、2018年-2023年
・主要企業における生物学的同等ペプチド医薬品のグローバル売上シェア、2022年
・主要企業における生物学的同等ペプチド医薬品のグローバル販売量、2018年-2023年
・主要企業における生物学的同等ペプチド医薬品のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Eli Lilly and Company、 Alvogen、 Pfenex、 HEC Pharm、 Bachem、 Bharat Pharmaceuticals、 Kingpep Biotechnology、 Ambio Pharmaceuticals、 Jiangsu Sinopep Allsino Biopharmaceutical、 Shanghai Shyndec Pharmaceutical、 Shenzhen Salubris Pharmaceuticals、 Shanghai United Cell Biotechnology、 Shenzhen JYMed Technology、 Wuxi Asiapeptide Biotechnology

*************************************************************

・調査・分析レポートの概要
生物学的同等ペプチド医薬品市場の定義
市場セグメント
世界の生物学的同等ペプチド医薬品市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の生物学的同等ペプチド医薬品市場規模
世界の生物学的同等ペプチド医薬品市場規模：2022年 VS 2029年
世界の生物学的同等ペプチド医薬品市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの生物学的同等ペプチド医薬品の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の生物学的同等ペプチド医薬品製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：テリパラチド（フォルテオ）、テドゥグルチド（ガテックス）、リラグルチド（ビクトーザ）
生物学的同等ペプチド医薬品のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：短腸症候群、骨粗鬆症、2型糖尿病、その他
生物学的同等ペプチド医薬品の用途別グローバル売上・予測

・地域別市場分析
地域別生物学的同等ペプチド医薬品市場規模 2022年と2029年
地域別生物学的同等ペプチド医薬品売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Eli Lilly and Company、 Alvogen、 Pfenex、 HEC Pharm、 Bachem、 Bharat Pharmaceuticals、 Kingpep Biotechnology、 Ambio Pharmaceuticals、 Jiangsu Sinopep Allsino Biopharmaceutical、 Shanghai Shyndec Pharmaceutical、 Shenzhen Salubris Pharmaceuticals、 Shanghai United Cell Biotechnology、 Shenzhen JYMed Technology、 Wuxi Asiapeptide Biotechnology
...

This research report provides a comprehensive analysis of the Bioequivalent Peptide Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Bioequivalent Peptide Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Bioequivalent Peptide Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Bioequivalent Peptide Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Bioequivalent Peptide Drugs market presents opportunities for various stakeholders, including Short Bowel Syndrome, Osteoporosis. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Bioequivalent Peptide Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Bioequivalent Peptide Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The development and production of bioequivalent peptide drugs usually requires detailed comparison and analysis, including in vitro and in vivo experimental evaluation, and comparison of clinical trial data. Bioequivalent peptide drugs have a wide range of applications in drug replacement, therapeutic expansion, and biosimilars.
Key Features:
The research report on the Bioequivalent Peptide Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Bioequivalent Peptide Drugs market.
Market Overview: The report provides a comprehensive overview of the Bioequivalent Peptide Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Teriparatide(Forteo), Teduglutide(Gattex)), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Bioequivalent Peptide Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Bioequivalent Peptide Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Bioequivalent Peptide Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Bioequivalent Peptide Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Bioequivalent Peptide Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Bioequivalent Peptide Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Bioequivalent Peptide Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Bioequivalent Peptide Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Bioequivalent Peptide Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Teriparatide(Forteo)
Teduglutide(Gattex)
Liraglutide(Victoza)
Market segment by Application
Short Bowel Syndrome
Osteoporosis
Type 2 Diabetes
Others
Global Bioequivalent Peptide Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Eli Lilly and Company
Alvogen
Pfenex
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Ambio Pharmaceuticals
Jiangsu Sinopep Allsino Biopharmaceutical
Shanghai Shyndec Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Shanghai United Cell Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bioequivalent Peptide Drugs, market overview.
Chapter 2: Global Bioequivalent Peptide Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Bioequivalent Peptide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bioequivalent Peptide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Bioequivalent Peptide Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Bioequivalent Peptide Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Bioequivalent Peptide Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Bioequivalent Peptide Drugs Overall Market Size
2.1 Global Bioequivalent Peptide Drugs Market Size: 2022 VS 2029
2.2 Global Bioequivalent Peptide Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Bioequivalent Peptide Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Bioequivalent Peptide Drugs Players in Global Market
3.2 Top Global Bioequivalent Peptide Drugs Companies Ranked by Revenue
3.3 Global Bioequivalent Peptide Drugs Revenue by Companies
3.4 Global Bioequivalent Peptide Drugs Sales by Companies
3.5 Global Bioequivalent Peptide Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Bioequivalent Peptide Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Bioequivalent Peptide Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Bioequivalent Peptide Drugs Players in Global Market
3.8.1 List of Global Tier 1 Bioequivalent Peptide Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Bioequivalent Peptide Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Bioequivalent Peptide Drugs Market Size Markets, 2022 & 2029
4.1.2 Teriparatide(Forteo)
4.1.3 Teduglutide(Gattex)
4.1.4 Liraglutide(Victoza)
4.2 By Type – Global Bioequivalent Peptide Drugs Revenue & Forecasts
4.2.1 By Type – Global Bioequivalent Peptide Drugs Revenue, 2018-2023
4.2.2 By Type – Global Bioequivalent Peptide Drugs Revenue, 2024-2029
4.2.3 By Type – Global Bioequivalent Peptide Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Bioequivalent Peptide Drugs Sales & Forecasts
4.3.1 By Type – Global Bioequivalent Peptide Drugs Sales, 2018-2023
4.3.2 By Type – Global Bioequivalent Peptide Drugs Sales, 2024-2029
4.3.3 By Type – Global Bioequivalent Peptide Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Bioequivalent Peptide Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Bioequivalent Peptide Drugs Market Size, 2022 & 2029
5.1.2 Short Bowel Syndrome
5.1.3 Osteoporosis
5.1.4 Type 2 Diabetes
5.1.5 Others
5.2 By Application – Global Bioequivalent Peptide Drugs Revenue & Forecasts
5.2.1 By Application – Global Bioequivalent Peptide Drugs Revenue, 2018-2023
5.2.2 By Application – Global Bioequivalent Peptide Drugs Revenue, 2024-2029
5.2.3 By Application – Global Bioequivalent Peptide Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Bioequivalent Peptide Drugs Sales & Forecasts
5.3.1 By Application – Global Bioequivalent Peptide Drugs Sales, 2018-2023
5.3.2 By Application – Global Bioequivalent Peptide Drugs Sales, 2024-2029
5.3.3 By Application – Global Bioequivalent Peptide Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Bioequivalent Peptide Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Bioequivalent Peptide Drugs Market Size, 2022 & 2029
6.2 By Region – Global Bioequivalent Peptide Drugs Revenue & Forecasts
6.2.1 By Region – Global Bioequivalent Peptide Drugs Revenue, 2018-2023
6.2.2 By Region – Global Bioequivalent Peptide Drugs Revenue, 2024-2029
6.2.3 By Region – Global Bioequivalent Peptide Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Bioequivalent Peptide Drugs Sales & Forecasts
6.3.1 By Region – Global Bioequivalent Peptide Drugs Sales, 2018-2023
6.3.2 By Region – Global Bioequivalent Peptide Drugs Sales, 2024-2029
6.3.3 By Region – Global Bioequivalent Peptide Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Bioequivalent Peptide Drugs Revenue, 2018-2029
6.4.2 By Country – North America Bioequivalent Peptide Drugs Sales, 2018-2029
6.4.3 US Bioequivalent Peptide Drugs Market Size, 2018-2029
6.4.4 Canada Bioequivalent Peptide Drugs Market Size, 2018-2029
6.4.5 Mexico Bioequivalent Peptide Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Bioequivalent Peptide Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Bioequivalent Peptide Drugs Sales, 2018-2029
6.5.3 Germany Bioequivalent Peptide Drugs Market Size, 2018-2029
6.5.4 France Bioequivalent Peptide Drugs Market Size, 2018-2029
6.5.5 U.K. Bioequivalent Peptide Drugs Market Size, 2018-2029
6.5.6 Italy Bioequivalent Peptide Drugs Market Size, 2018-2029
6.5.7 Russia Bioequivalent Peptide Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Bioequivalent Peptide Drugs Market Size, 2018-2029
6.5.9 Benelux Bioequivalent Peptide Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Bioequivalent Peptide Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Bioequivalent Peptide Drugs Sales, 2018-2029
6.6.3 China Bioequivalent Peptide Drugs Market Size, 2018-2029
6.6.4 Japan Bioequivalent Peptide Drugs Market Size, 2018-2029
6.6.5 South Korea Bioequivalent Peptide Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Bioequivalent Peptide Drugs Market Size, 2018-2029
6.6.7 India Bioequivalent Peptide Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Bioequivalent Peptide Drugs Revenue, 2018-2029
6.7.2 By Country – South America Bioequivalent Peptide Drugs Sales, 2018-2029
6.7.3 Brazil Bioequivalent Peptide Drugs Market Size, 2018-2029
6.7.4 Argentina Bioequivalent Peptide Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Bioequivalent Peptide Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Bioequivalent Peptide Drugs Sales, 2018-2029
6.8.3 Turkey Bioequivalent Peptide Drugs Market Size, 2018-2029
6.8.4 Israel Bioequivalent Peptide Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Bioequivalent Peptide Drugs Market Size, 2018-2029
6.8.6 UAE Bioequivalent Peptide Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Eli Lilly and Company
7.1.1 Eli Lilly and Company Company Summary
7.1.2 Eli Lilly and Company Business Overview
7.1.3 Eli Lilly and Company Bioequivalent Peptide Drugs Major Product Offerings
7.1.4 Eli Lilly and Company Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Eli Lilly and Company Key News & Latest Developments
7.2 Alvogen
7.2.1 Alvogen Company Summary
7.2.2 Alvogen Business Overview
7.2.3 Alvogen Bioequivalent Peptide Drugs Major Product Offerings
7.2.4 Alvogen Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Alvogen Key News & Latest Developments
7.3 Pfenex
7.3.1 Pfenex Company Summary
7.3.2 Pfenex Business Overview
7.3.3 Pfenex Bioequivalent Peptide Drugs Major Product Offerings
7.3.4 Pfenex Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Pfenex Key News & Latest Developments
7.4 HEC Pharm
7.4.1 HEC Pharm Company Summary
7.4.2 HEC Pharm Business Overview
7.4.3 HEC Pharm Bioequivalent Peptide Drugs Major Product Offerings
7.4.4 HEC Pharm Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.4.5 HEC Pharm Key News & Latest Developments
7.5 Bachem
7.5.1 Bachem Company Summary
7.5.2 Bachem Business Overview
7.5.3 Bachem Bioequivalent Peptide Drugs Major Product Offerings
7.5.4 Bachem Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Bachem Key News & Latest Developments
7.6 Bharat Pharmaceuticals
7.6.1 Bharat Pharmaceuticals Company Summary
7.6.2 Bharat Pharmaceuticals Business Overview
7.6.3 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Major Product Offerings
7.6.4 Bharat Pharmaceuticals Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Bharat Pharmaceuticals Key News & Latest Developments
7.7 Kingpep Biotechnology
7.7.1 Kingpep Biotechnology Company Summary
7.7.2 Kingpep Biotechnology Business Overview
7.7.3 Kingpep Biotechnology Bioequivalent Peptide Drugs Major Product Offerings
7.7.4 Kingpep Biotechnology Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Kingpep Biotechnology Key News & Latest Developments
7.8 Ambio Pharmaceuticals
7.8.1 Ambio Pharmaceuticals Company Summary
7.8.2 Ambio Pharmaceuticals Business Overview
7.8.3 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Major Product Offerings
7.8.4 Ambio Pharmaceuticals Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Ambio Pharmaceuticals Key News & Latest Developments
7.9 Jiangsu Sinopep Allsino Biopharmaceutical
7.9.1 Jiangsu Sinopep Allsino Biopharmaceutical Company Summary
7.9.2 Jiangsu Sinopep Allsino Biopharmaceutical Business Overview
7.9.3 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Major Product Offerings
7.9.4 Jiangsu Sinopep Allsino Biopharmaceutical Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Jiangsu Sinopep Allsino Biopharmaceutical Key News & Latest Developments
7.10 Shanghai Shyndec Pharmaceutical
7.10.1 Shanghai Shyndec Pharmaceutical Company Summary
7.10.2 Shanghai Shyndec Pharmaceutical Business Overview
7.10.3 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Major Product Offerings
7.10.4 Shanghai Shyndec Pharmaceutical Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Shanghai Shyndec Pharmaceutical Key News & Latest Developments
7.11 Shenzhen Salubris Pharmaceuticals
7.11.1 Shenzhen Salubris Pharmaceuticals Company Summary
7.11.2 Shenzhen Salubris Pharmaceuticals Business Overview
7.11.3 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Major Product Offerings
7.11.4 Shenzhen Salubris Pharmaceuticals Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Shenzhen Salubris Pharmaceuticals Key News & Latest Developments
7.12 Shanghai United Cell Biotechnology
7.12.1 Shanghai United Cell Biotechnology Company Summary
7.12.2 Shanghai United Cell Biotechnology Business Overview
7.12.3 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Major Product Offerings
7.12.4 Shanghai United Cell Biotechnology Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Shanghai United Cell Biotechnology Key News & Latest Developments
7.13 Shenzhen JYMed Technology
7.13.1 Shenzhen JYMed Technology Company Summary
7.13.2 Shenzhen JYMed Technology Business Overview
7.13.3 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Major Product Offerings
7.13.4 Shenzhen JYMed Technology Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Shenzhen JYMed Technology Key News & Latest Developments
7.14 Wuxi Asiapeptide Biotechnology
7.14.1 Wuxi Asiapeptide Biotechnology Company Summary
7.14.2 Wuxi Asiapeptide Biotechnology Business Overview
7.14.3 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Major Product Offerings
7.14.4 Wuxi Asiapeptide Biotechnology Bioequivalent Peptide Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Wuxi Asiapeptide Biotechnology Key News & Latest Developments
8 Global Bioequivalent Peptide Drugs Production Capacity, Analysis
8.1 Global Bioequivalent Peptide Drugs Production Capacity, 2018-2029
8.2 Bioequivalent Peptide Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Bioequivalent Peptide Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Bioequivalent Peptide Drugs Supply Chain Analysis
10.1 Bioequivalent Peptide Drugs Industry Value Chain
10.2 Bioequivalent Peptide Drugs Upstream Market
10.3 Bioequivalent Peptide Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Bioequivalent Peptide Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 生物学的同等ペプチド医薬品のグローバル市場展望 2023年-2029年：テリパラチド（フォルテオ）、テドゥグルチド（ガテックス）、リラグルチド（ビクトーザ）(Bioequivalent Peptide Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

生物学的同等ペプチド医薬品のグローバル市場展望 2023年-2029年：テリパラチド（フォルテオ）、テドゥグルチド（ガテックス）、リラグルチド（ビクトーザ）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp